Literature DB >> 20127132

In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.

G P Neupane1, D-M Kim.   

Abstract

Iron plays a major role in the growth and virulence of ferrophilic organisms like Vibrio vulnificus. People who reside in the coastal areas with raw fish eating habits have a high risk of Vibrio infection and aggressive therapy can only reduce their mortality. We investigated the in vitro efficacy of ciprofloxacin, a bactericidal drug used in V. vulnificus patients, and the orally active iron chelator deferasirox against V. vulnificus infection. We performed in vitro time-kill studies on two ATCC strains and one clinical isolate of V. vulnificus collected from a patient admitted to Chosun University Hospital with either ciprofloxacin or iron chelator deferasirox alone and the two drugs in combination. The combination of an iron chelator plus an antibiotic creates a novel form of synergism at 24 h. The antimicrobial effect of deferasirox may be ascribed to its ability to deplete iron that would otherwise be used for bacterial growth. Combination therapy with ciprofloxacin plus deferasirox has potential clinical application by lowering the iron availability against a ferrophilic organism like V. vulnificus infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127132     DOI: 10.1007/s10096-010-0875-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Authors:  Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

2.  In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.

Authors:  Dong-Min Kim; Yong Lym; Sook Jin Jang; Hulin Han; Young Gi Kim; Choon-Hae Chung; Soon Pyo Hong
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.

Authors:  Hung-Jen Tang; Ming-Chung Chang; Wen-Chien Ko; Kun-Yen Huang; Chih-Lung Lee; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 4.  Iron and infection: the heart of the matter.

Authors:  John J Bullen; Henry J Rogers; Paul B Spalding; Charles G Ward
Journal:  FEMS Immunol Med Microbiol       Date:  2005-03-01

5.  Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987.

Authors:  K C Klontz; S Lieb; M Schreiber; H T Janowski; L M Baldy; R A Gunn
Journal:  Ann Intern Med       Date:  1988-08-15       Impact factor: 25.391

Review 6.  Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy.

Authors:  Shyh-Ren Chiang; Yin-Ching Chuang
Journal:  J Microbiol Immunol Infect       Date:  2003-06       Impact factor: 4.399

7.  A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus.

Authors:  Choon-Mee Kim; Yong-Jin Park; Sung-Heui Shin
Journal:  J Infect Dis       Date:  2007-10-31       Impact factor: 5.226

Review 8.  Vibrio vulnificus infection: diagnosis and treatment.

Authors:  Michael H Bross; Kathleen Soch; Robert Morales; Rayford B Mitchell
Journal:  Am Fam Physician       Date:  2007-08-15       Impact factor: 3.292

9.  Siderophore production by Vibrio vulnificus.

Authors:  L M Simpson; J D Oliver
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

10.  Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.

Authors:  Dong-Min Kim; Hong Sung Cho; Ji-In Kang; Hyong Sun Kim; Chi Young Park
Journal:  J Infect       Date:  2008-10-18       Impact factor: 6.072

View more
  9 in total

1.  Reply to "The Dual personality of iron chelators: growth inhibitors or promoters?".

Authors:  Daniel V Zurawski; Anna C Jacobs; Mitchell G Thompson; Thomas J Palys
Journal:  Antimicrob Agents Chemother       Date:  2013-05       Impact factor: 5.191

2.  Quantitative PCR and in vivo efficacy of antibiotics in the treatment of Vibrio vulnificus infection in a mouse model.

Authors:  G P Neupane; D-M Kim; N R Yun; S-H Shin; S-C Lim; C-H Choi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-21       Impact factor: 3.267

3.  Vibrio vulnificus DNA load and mortality.

Authors:  Dong-Min Kim; Sook-In Jung; Hee-Chang Jang; Chang Seop Lee; Sun Hee Lee; Na Ra Yun; Ganesh Prasad Neupane; Kyung-Hwa Park
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

4.  Antibacterial activities of iron chelators against common nosocomial pathogens.

Authors:  Mitchell G Thompson; Brendan W Corey; Yuanzheng Si; David W Craft; Daniel V Zurawski
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

Review 5.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

6.  pH level as a marker for predicting death among patients with Vibrio vulnificus infection, South Korea, 2000-2011.

Authors:  Na Ra Yun; Dong-Min Kim; Jun Lee; Mi Ah Han
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

Review 7.  Controversies on the Consequences of Iron Overload and Chelation in MDS.

Authors:  Francesca Vinchi; Saskia Hell; Uwe Platzbecker
Journal:  Hemasphere       Date:  2020-05-27

Review 8.  Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles' heel of antibiotic-resistant microbes.

Authors:  Bruce E Holbein; M Trisha C Ang; David S Allan; Wangxue Chen; Christian Lehmann
Journal:  Environ Chem Lett       Date:  2021-04-23       Impact factor: 9.027

Review 9.  Tuning the Anti(myco)bacterial Activity of 3-Hydroxy-4-pyridinone Chelators through Fluorophores.

Authors:  Maria Rangel; Tânia Moniz; André M N Silva; Andreia Leite
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.